Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity

Micro-Abstract Polymorphisms of CYP2D6 were analyzed in 55 patients with non–small-cell lung cancer (NSCLC) who experienced gefitinib-induced hepatotoxicity. Their genotypic distribution was similar to the known distribution in the general Japanese population. However, in patients taking CYP3A4-inhi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2013-09, Vol.14 (5), p.502-507
Hauptverfasser:	Takimoto, Takayuki, Kijima, Takashi, Otani, Yasushi, Nonen, Shinpei, Namba, Yoshinobu, Mori, Masahide, Yokota, Soichiro, Minami, Seigo, Komuta, Kiyoshi, Uchida, Junji, Imamura, Fumio, Furukawa, Mitsugi, Tsuruta, Naotoshi, Fujio, Yasushi, Azuma, Junichi, Tachibana, Isao, Kumanogoh, Atsushi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - complications Adenocarcinoma - genetics Adenocarcinoma - pathology Adult Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - complications Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - pathology Case-Control Studies CYP2D6 Cytochrome P-450 CYP2D6 - genetics Erlotinib Female Follow-Up Studies Gefitinib Hematology, Oncology and Palliative Medicine Hepatotoxicity Humans Liver Diseases - diagnosis Liver Diseases - etiology Lung Neoplasms - complications Lung Neoplasms - genetics Lung Neoplasms - pathology Male Middle Aged Neoplasm Staging Polymorphism, Genetic - genetics Polymorphisms Prognosis Protein Kinase Inhibitors - adverse effects Pulmonary/Respiratory Quinazolines - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Polymorphisms of CYP2D6 were analyzed in 55 patients with non–small-cell lung cancer (NSCLC) who experienced gefitinib-induced hepatotoxicity. Their genotypic distribution was similar to the known distribution in the general Japanese population. However, in patients taking CYP3A4-inhibitory drugs, gefitinib retreatment caused hepatotoxicity more frequently in those with CYP2D6 allele 5 or 10 than in those with normal alleles. Moreover, a switch to erlotinib was not hepatotoxic in all 17 patients with these alleles.
ISSN:	1525-7304 1938-0690
DOI:	10.1016/j.cllc.2013.03.003